Hidden Risks: Cognitive Decline, Anemia, and Kidney Disease Impacting Heart Failure
"Uncover how addressing cognitive impairment, anemia, and kidney disease can significantly improve outcomes for heart failure patients and reduce hospital readmissions."
Heart failure (HF) remains a leading cause of hospitalization and a significant burden on the healthcare system. While immediate medical management and patient counseling are standard practice, certain underlying conditions often go unnoticed, significantly impacting patient outcomes and increasing the likelihood of readmission.
Non-adherence to prescribed diets and medications is a well-recognized factor in HF readmissions. However, other contributing factors, such as cognitive impairment, anemia, and chronic kidney disease (CKD), also play a crucial role. Recognizing and addressing these factors is essential for holistic patient care and improved outcomes.
This article explores how these often-overlooked conditions can impact heart failure management and outcomes, drawing on recent research to highlight their prevalence and potential interventions. By focusing on these addressable factors, healthcare providers can develop more effective strategies to reduce hospital readmissions and improve the quality of life for individuals living with heart failure.
Cognition and Heart Failure Care
The Heart Failure Society of America scientific statement says cognition is critical to many self-care activities needed to manage heart failure (HF). Cognitive impairment can affect self-care, medication management, function, independence, and life expectancy, and has important implications for prognosis. CMS began reducing Medicare payments for eligible hospitals with excess readmissions in October 2012 through the Hospital Readmissions Reduction Program (HRRP); HF is among the conditions included in its readmission measure.
Readmission Prevention and Its Challenges
A 2025 scoping review set out to examine how published studies define and measure preventable readmissions for patients with HF, including the judgment criteria and reasoning used. The American Heart Association's Target: HF Readmission Checklist is intended to help care teams identify gaps in transitional care that may contribute to potentially preventable readmissions. A 2026 article identifies follow-up care after discharge as an important part of a plan to reduce readmission risk. These sources describe approaches and questions in readmission prevention, rather than establishing that every readmission is preventable.
Unmasking the Silent Threats: Cognitive Impairment, Anemia, and CKD in Heart Failure
A recent study evaluated 44 heart failure patients to determine the prevalence of cognitive impairment, anemia, and chronic kidney disease. The results revealed significant findings that highlight the importance of addressing these conditions.
- Cognitive Impairment: 25% of patients exhibited cognitive impairment, which can hinder their ability to adhere to medication schedules, dietary recommendations, and follow-up appointments.
- Anemia: A substantial 63.6% of patients were anemic, which negatively impacts cardiac function and overall well-being. Iron deficiency was identified in 45% of anemic patients.
- Chronic Kidney Disease (CKD): 40.9% of patients had CKD, requiring careful adjustments to medication regimens, particularly diuretics and ACE inhibitors.
Research on Readmission Prevention
A 2025 review in the *Journal of Clinical Medicine* describes HF readmissions as a continuing challenge associated with morbidity, mortality, and healthcare costs. It reports that rehospitalization rates remain high, particularly within the first 30 days after discharge, despite advances in medical and device-based therapies. The review aims to evaluate factors associated with HF readmissions and prevention strategies.
Limits of the Evidence
A Swedish prospective cohort study notes that the Montreal Cognitive Assessment (MoCA) has been criticized for low specificity in detecting mild cognitive impairment in populations with a low base rate of cognitive decline. A separate narrative review identifies substantial heterogeneity among studies in patient populations, HF phenotypes, cognitive assessments, definitions of cognitive impairment, and confounder adjustment, limiting comparability and the strength of pooled conclusions. In a retrospective chronic kidney disease cohort, the authors caution that the observed association between anemia and length of stay may reflect an unmeasured factor related to both, rather than anemia itself.
Cognitive Impairment and Outcomes
A meta-analysis found that, compared with patients without cognitive impairment, patients with HF and cognitive impairment had a pooled adjusted risk ratio of 1.88 for all-cause mortality (95% CI 1.42–2.48) and 1.48 for readmission (95% CI 1.19–1.84). The pooled adjusted risk ratio for the combined endpoint of all-cause mortality or readmission was 1.53 (95% CI 1.35–1.73). Separately, a study of mild cognitive impairment reported that death and readmission within 30 days of discharge were more likely among affected patients (OR 2.00, p=0.001); it recorded 43 deaths (8%) and 122 readmissions (21%) in that period. These findings concern different analyses and measures and should not be treated as identical estimates.
Turning Awareness into Action: Improving Heart Failure Outcomes
The study's findings call for targeted interventions to address these prevalent factors. For cognitively impaired patients, involving caregivers in education and medication management is crucial. Evaluating and correcting anemia, especially iron deficiency, can improve cardiac function and overall health. In patients with CKD, careful medication adjustments are necessary to avoid complications.
Managing Heart Failure Across Care Settings
A meta-analysis of multidisciplinary HF management programs examined their effectiveness in reducing hospital admission rates. Its abstract describes HF as a leading cause of hospitalization and readmission in many hospitals worldwide. A 2025 JACC abstract says data comparing 30-day readmission patterns in HF with preserved versus reduced ejection fraction are limited, and describes an analysis of all-cause and HF-specific readmissions, predictors, and mortality using a national database. Together, these sources point to ongoing questions about both care programs and differences between HF groups.
Tracking Readmissions and Outcomes
A 2023 study using national data examined trends, predictors, and costs associated with multiple readmissions after HF hospitalization. Its source snippet reports that 25% of patients are readmitted within one month of discharge and approximately 50% within six months, with a smaller group experiencing multiple readmissions and contributing disproportionately to healthcare costs. A separate study of national Medicare data examined adjusted 30-day mortality, readmission, and home time—days alive and out of healthcare facilities—among patients hospitalized from January 2016 through December 2022, comparing prepandemic (2016–2019) and postpandemic (2020–2022) periods. The HF Stats 2026 report is described as the fourth iteration of the HFSA's annually updated U.S. reference on HF epidemiology and outcomes.
Care After Hospitalization
A 2024 Truveta case study says HF readmission rates have worsened over the past decade despite advances in guideline-directed medical therapy. It describes acute inpatient decongestion as important for mitigating HF morbidity and mortality, and notes that loop diuretics remain a cornerstone of treatment requiring careful, frequent dose adjustments. A 2021 HIMSS case study reports that a 30-day CMS HF readmission prevention program was a key component of Homestead Hospital's Magnet Recognition process, with nursing leadership guiding research, education, and changes to the existing process.
While age is a non-modifiable factor, recognizing and addressing these co-existing conditions offers a clear path towards improving outcomes and reducing hospital readmissions for heart failure patients. By integrating these considerations into routine care, healthcare providers can deliver more effective and personalized treatment plans.
Ultimately, a holistic approach that addresses cognitive function, anemia, and kidney health, alongside traditional heart failure treatments, holds the key to improving the lives of individuals living with this chronic condition and reducing the burden on the healthcare system.